Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H15BrF2N4O2 |
| Molecular Weight | 437.238 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(NC(=O)NC2=CC=C(F)C=C2F)C=C1C3=C(Br)C=NN3C
InChI
InChIKey=COSPVUFTLGQDQL-UHFFFAOYSA-N
InChI=1S/C18H15BrF2N4O2/c1-25-17(13(19)9-22-25)12-8-11(4-6-16(12)27-2)23-18(26)24-15-5-3-10(20)7-14(15)21/h3-9H,1-2H3,(H2,23,24,26)
| Molecular Formula | C18H15BrF2N4O2 |
| Molecular Weight | 437.238 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:58:22 UTC 2023
by
admin
on
Sat Dec 16 17:58:22 UTC 2023
|
| Record UNII |
4ZA73QEW2P
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C66885
Created by
admin on Sat Dec 16 17:58:22 UTC 2023 , Edited by admin on Sat Dec 16 17:58:22 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
300000034287
Created by
admin on Sat Dec 16 17:58:22 UTC 2023 , Edited by admin on Sat Dec 16 17:58:22 UTC 2023
|
PRIMARY | |||
|
4ZA73QEW2P
Created by
admin on Sat Dec 16 17:58:22 UTC 2023 , Edited by admin on Sat Dec 16 17:58:22 UTC 2023
|
PRIMARY | |||
|
DB12555
Created by
admin on Sat Dec 16 17:58:22 UTC 2023 , Edited by admin on Sat Dec 16 17:58:22 UTC 2023
|
PRIMARY | |||
|
NELOTANSERIN
Created by
admin on Sat Dec 16 17:58:22 UTC 2023 , Edited by admin on Sat Dec 16 17:58:22 UTC 2023
|
PRIMARY | |||
|
C83996
Created by
admin on Sat Dec 16 17:58:22 UTC 2023 , Edited by admin on Sat Dec 16 17:58:22 UTC 2023
|
PRIMARY | |||
|
9109
Created by
admin on Sat Dec 16 17:58:22 UTC 2023 , Edited by admin on Sat Dec 16 17:58:22 UTC 2023
|
PRIMARY | |||
|
CHEMBL598172
Created by
admin on Sat Dec 16 17:58:22 UTC 2023 , Edited by admin on Sat Dec 16 17:58:22 UTC 2023
|
PRIMARY | |||
|
839713-36-9
Created by
admin on Sat Dec 16 17:58:22 UTC 2023 , Edited by admin on Sat Dec 16 17:58:22 UTC 2023
|
PRIMARY | |||
|
C546600
Created by
admin on Sat Dec 16 17:58:22 UTC 2023 , Edited by admin on Sat Dec 16 17:58:22 UTC 2023
|
PRIMARY | |||
|
DTXSID40232868
Created by
admin on Sat Dec 16 17:58:22 UTC 2023 , Edited by admin on Sat Dec 16 17:58:22 UTC 2023
|
PRIMARY | |||
|
11683556
Created by
admin on Sat Dec 16 17:58:22 UTC 2023 , Edited by admin on Sat Dec 16 17:58:22 UTC 2023
|
PRIMARY | |||
|
UU-15
Created by
admin on Sat Dec 16 17:58:22 UTC 2023 , Edited by admin on Sat Dec 16 17:58:22 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET->INVERSE AGONIST |
Was under development for the treatment of insomnia. Development was halted in December 2008 because the substance did not meet the trial's effectiveness endpoints.recently, nelotanserin has been repurposed for the treatment of Lewy body disease.
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
